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ABSTRACT 
Objectives: To review current experience with Pseudomonas 
aeruginosa bacteremia and compare outcome of patients 
treated with single-drug, versus combination therapy. 
Methods: The charts of all patients with P aeruginosa bac- 
teremia between 1990 and 1992 were reviewed, and pertinent 
demographic, clinical, and bacteriologic data were retrieved. 
In addition, similar data were collected from a series of patients 
with P aeruginosa bacteremia from the literature of the past 20 
years. 
Results: One hundred and twenty-three episodes of F! aeru- 
ginosa bacteremia in 121 patients were identified. Most patients 
were older than 70 years, had at least one underlying condi- 
tion, and had acquired the infection in the hospital. Attributable 
mortality was 34%. After exclusion for early mortality and inap- 
propriate therapy, 57 patients remained eligible for compari- 
son of outcome according to therapy protocol. Mortality from 
infection was equal between the group of 42 patients who 
received monotherapy and the 15 patients who received com- 
bination therapy (14% and 13%, respectively). The literature 
review revealed eight articles describing 21 to 410 spisodes of 
Pseudomonas bacteremia. The clinical characteristics of these 
series did not differ significantly from those of the present series. 
Conclusions: Incidence, epidemiology, clinical characteristics, 
and outcome of pseudomonas sepsis did not change signifi- 
cantly over the past 2 decades. Appropriate monotherapy was 
as effective as combination drug therapy for individuals with 
pseudomonas bacteremia surviving the first 2 days of infection. 
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Pseudomonas aeruginosa infections continue to be 
responsible for considerable morbidity and mortality in 
compromised and hospitalized patients. In spite of long- 
term recognition of the syndrome of Pseudomonas bac- 
teremia and availability of effective drugs, the treatment 
of choice is still controversial, especially as to whether 
combination therapy is superior to monotherapy. A lit- 
erature review encompassing the past 20 years revealed 
much information concerning the epidemiology, demog- 
raphy, underlying conditions, place of acquisition, foci of 
infection, risk factors for mortality, and outcome associ- 
ated with I! aeruginosa bacteremia, but did not supply 
a satisfactory answer to the controversy.1-9 
The authors conducted a retrospective analysis of 
123 episodes of I? aeruginosa bacteremia over a period 
of 3 years, reviewed epidemiologic and clinical charac- 
teristics in comparison with previous similar series, and 
compared outcome for monotherapy versus combination 
drug therapy. 
MATERIAL and METHODS 
The Tel-Aviv Sourasky Medical Center is a 950-bed ter- 
tiary hospital located in central Tel-Aviv, serving a mostly 
elderly population. All patients who had I? aeruginosa 
in blood cultures during the period 1990 to 1992 were 
included in this analysis. Their medical records were care- 
fully reviewed and pertinent demographic and medical 
data were retrieved. 
The following definitions were employed: 
1. 
2. 
3. 
4. 
5. 
Neutropenia: Polymorphonuclear count of less than 
1000&L. 
Hospital-acquired bacteremia: Bacteremia that 
occurred more than 48 hours after admission, or less 
than 48 hours following an invasive procedure. 
Death attributed to infection: Death occurring before 
resolution of the septic manifestations, and in the 
absence of another obvious direct cause of death. 
Death not associated with infection: All other deaths 
occurring during hospitalization. 
Empiric therapy: Antibiotics given from the onset of 
clinical signs attributed to bacteremia to the day that 
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6. 
7. 
8. 
9. 
antimicrobial susceptibility of the isolate was 
reported. 
Definitive therapy: Drugs given after antimicrobial 
susceptibility was reported. The interval between 
empiric and definitive therapy ranged from 2 to 4 
days. 
Appropriate antipseudomonal therapy. Monotherapy: 
Either a fluoroquinolone or a third generation 
cephalosporin or imipenem-cilastatin, to which the 
isolate was susceptible in vitro, given either alone or 
in combination with another drug to which the 
organism was resistant. The use of either a ureido- 
penicillin or an aminoglycoside alone was not 
considered appropriate even if the isolate was sus- 
ceptible to the drug. 
Combination drug therapy: The use of one of the fol- 
lowing drugs: a fluoroquinolone, a third generation 
cephalosporin, imipenem-cilastatin, or a ureidopeni- 
cillin in combination with an aminoglycoside when 
the isolate was susceptible to both. 
No therapy: The use of either no antibiotics at all or 
the administration of antibiotics for less than 24 
hours. This occurred mostly in patients who died in 
the first 48 hours of bacteremia. 
Identification of p aeruginosa and antibiotic suscepti- 
bility testing was performed using an automated system 
(Sensititer, Radiometer, Copenhagen, Denmark). Statisti- 
cal analysis was performed using the chi-squared or 
Fisher’s exact test as appropriate. A P value of I 0.05 was 
considered significant. 
RESULTS 
One hundred and twenty-three episodes of p aeruginosa 
bacteremia in 121 patients were identified during the 
study period (1990- 1992), representing 1.66 episodes 
per 1000 admissions. The patients’ ages ranged between 
12 and 94 years (mean, 70; median, 72); 79 patients (65%) 
were 70 years or older; 81 patients (67%) were males. 
Table 1. Sources of Infection in Community- and Hospital- 
Acquired Pseudomonas Bacteremia in 120 Episodes” 
Community Acquired Hospital Acquired 
Source of Infection n = 24 (700%) n = 96 (100%) 
Urinary tract 3 (12%) 37 (39%) 
Respiratory tract 5 (21%) 17 (18%) 
Intra-abdominal 11 (11%) 
Vascular lines 1 (4%) 4 (4%) 
Soft tissue 1 (4%) 4 (4%) 
Perianal 1 (1%) 
Meningitis 1 (4%) 1 (1%) 
Unknown 13 (54%) 21 (22%) 
*An additional three episodes were excluded due to acquisition at other 
institutions. 
Table 2. Comparison of the Four Treatment Groups 
Group 1 Group 2 Group 3 Group 4 
(emp t/def+) (emp-/def+) (emp-/def-) (none) 
Number of patients 23 41 29 19 
(n = 112) 
Mean age 72 +- 16 67i 17 69211 77 2 9 
(70 -t 14 y) 
Risk factors 
Malignancy 4 (17%) 14 (34%) 16 (55%) 5 (26%) 
(n = 39) (35%) 
Neutropenia 3 (13%) 2 (5%) 5 (17%) 2 (11%) 
(n = 12) (11%) 
Mortality 
Overall 6 (26%) 11 (27%) 14 (48%) 15 (79%) 
(n = 46) (40%) 
Infection-related 4 (17%) 7 (17%) 13 (45%) 15 (79%) 
(n = 39) (35%) 
*Nine patients could not be categorized. 
emp+ = appropriate empiric therapy; def+ = appropriate definitive therapy; 
emp- = inappropriate empiric therapy; def- = inappropriate definitive therapy. 
The majority of the patients had at least one under- 
lying condition, the most common of which were: malig- 
nancy 35% (42/121), steroid therapy 19% (23/121), 
diabetes mellitus 16% (19/121), and neutropenia 11% 
(13/121). 
Of the 123 infectious episodes, 99 (80%) were hos- 
pital acquired. The sources of bacteremia were primarily 
urinary and respiratory tract infections (Table 1). Resis- 
tance to antipseudomonal drugs among 96 hospital- 
acquired isolates was as follows: gentamicin, 43%; 
piperacillin, 29%; ceftazidime, 18%; ciprofloxacin, 17%; 
amikacin, 9%; and imipenem, 5%. Resistance among com- 
munity-acquired isolates was significantly different only 
for gentamicin (26%) and piperacillin (9%) (P I 0.05). 
Forty-nine patients (40.5%) died during hospitaliza- 
tion, but only 41 deaths (34% of the total) were attributed 
to pseudomonas infection. 
One hundred and twelve patients were divided into 
the following four groups according to the type of ther- 
apy (nine patients were excluded owing to absent or 
conflicting data): 
Group 1: appropriate empiric and appropriate defin- 
itive therapy (emp+/def+) = 23 patients. 
Group 2: inappropriate empiric and appropriate 
definitive therapy (emp-/def+) = 41 patients. 
Group 3: inappropriate empiric and inappropriate 
definitive therapy (emp-/def-) = 29 patients. 
Group 4: no therapy = 19 patients. 
Mortality from infection was identical (17%) in groups 
1 and 2 irrespective of appropriateness of empiric ther- 
apy (Table 2). The difference in mortality from infection 
between patients receiving appropriate definitive therapy 
(groups 1 and 2 combined) and patients receiving inap- 
propriate definitive therapy (group 3) was statistically sig- 
nificant (1 I/64 [17%] vs. 13/29 [45%], P < 0.05). 
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Table 3. Comparison of Monotherapy 
versus Combination Drug Therapy 
Monotherapy Two Drugs 
___- 
n (%) n (%) P Value 
Number of patients 42 (100%) 15 (100%) 
Age 2 70 years 27 (64%) 9 (60%) NS 
Risk factors 
Malignant disease 8 (19%) 7 (47%) 0.05 
Neutropenia 2 (5%) (7%) NS 
Hospital-acquired infection 37 (88%) 1: (93%) NS 
Mortality 
Overall 7 (17%) 7 (47%) 0.05 
Infection-related 6 (14%) 2 (13%) NS 
NS = not significant. 
Obviously, comparing the outcome of patients receiv- 
ing either monotherapy or combination drug therapy was 
applicable only to the 64 patients who received appro- 
priate definitive treatment (groups 1 and 2). Seven of 
these 64 patients were excluded from this analysis 
because of changes in the definitive therapy either from 
combination therapy to monotherapy or vice versa. Of 
the remaining 57 patients, 42 patients received monother- 
apy and 15 combination drug therapy. 
These two treatment groups did not differ signifi- 
cantly in terms of age, underlying conditions, or place of 
acquisition of infection (Table 3), although malignant dis- 
ease was somewhat more prevalent in the combination 
drug group (P = 0.05). Mortality from infection was equal 
in the two groups (14% and 13%, see Table 3). 
DISCUSSION 
A literature review of the clinical and epidemiologic fea- 
tures of l? aeruginosa bacteremia revealed no significant 
changes over the past 20 years. Comparison of several 
large series of P aeruginosa bacteremia published from 
I976 to 1996 showed striking similarities in clinical fea- 
tures and outcome among the different series (Table 4).2-9 
The only differences detected among these series con- 
cerned the incidence of Pseudomonas bacteremia per 
1000 admissions and the percentage of underlying malig- 
nant disease, reflecting most likely, differences in the pop- 
ulations from which the study patients were derived. 
Interestingly, and in spite of the varying underlying 
conditions, mortality due to infection remained surpris- 
ingly constant (38-48%) throughout these 2 decades, 
except for that reported in the most recent study, which 
is, so far, exceptional.” 
Historically, up to the late 1960s most Pseudomonas 
infections were fatal. The introduction of gentamicin and 
later carbenicillin, when used alone, improved prognosis 
only slightlylO However, the combination of carbenicillin 
and gentamicin was shown to be synergistic in vitro,” and 
resulted in a higher survival rate than either drug alone in 
experimental Paeruginosa infections in animal models.12-14 
Human studies involving, primarily, cancer patients with 
or without neutropenia also favored combination therapy, 
but included only a small number of cases of Pseudomonas 
bacteremia among others with gram-negative sepsis.15-” 
Following these findings, combination therapy with an 
Study period 
Number of episodes 
Male:Female 
Age 
Table 4. Characteristics of Pseudomonas Bacteremia from the Literature (1976-l 996) 
Baltch Bodey McKendrick Lechi Gallaghar Hi/f Ma/lo/as Wdal 
and et and et and et et et Present 
Griffin 2 al3 Gedde9 a/5 Wa tanakunakorn6 al 7 al8 al9 study 
1972-1975 1972-1981 1974-1980 1975-1981 1980-1984 1982-1986 1983-1989 1991-1994 1990-1992 
75 410 21 60 96 200 274 189 123 
1.8:1 1.3:1 1:l.l 1.6:l 1.9:1 2.2:1 2:i 2:l 
Mean 59 44 65* 64 59 
Range O-82 2-85 18-78 14-87 O-96 
270 (%) years 24 8 43 
Incidence 
(cases/i 000 admissions) 4.7 0.4 1.41 1.4 
Hospital-acquired (%) 97 81 71 85 65 77 80 
Stay to bacteremia (d)+ 12 22 20 
Focus 
Urinary (%) 28 15 14 17 27 29 
Pulmonary (%) 21 32 19 30 32 34 
Underlying malignancy (%) 33 100 57 66 24* 48 
Chemotherapy (%) 17 78 43 27 34 
Neutropenia (%) 13 69 52 26” 
Steroid therapy (“Y) 39 64 27 40 
Mortality 
Overall (%) 63 48 75 61 
Infection-related (%) 44 38 48 41 42 
*Median; +mean number of days of hospitalization from admission to bacteremia; *hematologic malignancy only: Q3000 neutrophils/pL. 
54 70 
12-94 
65 
1.5 1.66 
83 80 
17 
16 33 
16 18 
28 35 
17 
23 11 
22 19 
18 40 
11 34 
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antipseudomonal beta-lactam and an aminoglycoside 
became the standard therapy for Pseudomonas bac- 
teremia.” Later, when newer drugs, such as ceftazidime, 
imipenem-cilastatin, and quinolones were shown to be 
effective as single agents in the therapy of severe 
Pseudomonas infections, even in neutropenic patients,19-22 
the need for a second drug was questioned. 
To the authors’ knowledge, no prospective random- 
ized comparison between monotherapy and combination 
drug therapy has been done in a series of patients with 
Pseudomonas bacteremia. Bodey et al showed equal 
results when an antipseudomonal beta-lactam antibiotic 
was used with or without an aminoglycoside in patients 
with Pseudomonas bacteremia.3,23 However, the authors 
were cautious about recommending the use of an 
antipseudomonal penicillin as a single agent to treat seri- 
ous Pseudomonas infections3 Hilf et al, in a prospective, 
but not randomized study on Pseudomonas bacteremia, 
concluded that the use of combination therapy was asso- 
ciated with a significantly lower mortality than monother- 
apy (27% vs. 47%).’ In their study, 143 patients received 
combination therapy and 43 monotherapy However, 37 of 
these 43 patients received aminoglycoside alone, and six 
patients received beta-lactam alone (mostly a ureidopeni- 
~illin).~~~*~~~ Thus, most of these 43 patients would have 
been categorized as receiving inappropriate therapy 
according to the definitions presented in this report, and 
indeed, the mortality in these 43 patients was 47%, the 
same as in the inappropriately treated patients in the pre- 
sent study (group 3; 45%). Therefore, no conclusion can 
be drawn from this study concerning the effectiveness of 
single-drug therapy. Another retrospective study reviewing 
189 episodes of Paeruginosa bacteremia showed no dif- 
ference in outcome between patients receiving one drug 
or two or more.9 There are no details as to whether ureido- 
penicillins were included as monotherapy 
The present study, in spite of being retrospective and 
including a relatively small number of patients for com- 
parison, showed that monotherapy (with a cephalosporin, 
imipenem-cilastatin, or quinolone) given to 42 patients 
who survived the first 48 hours of I? aeruginosa bac- 
teremia, was as effective as combination drug therapy. 
Interestingly, in accordance with a recent study,9 and 
in contrast to an earlier one,3 in the present study no dif- 
ference was noted in outcome when appropriate therapy 
was begun early or only after drug susceptibility was 
reported (group 2 vs. group 1). However, the possible 
effect of the initial empiric therapy on early survival was 
not evaluated, and patients who died within the first 48 
hours were excluded from the final analysis. 
In conclusion, this study shows equal results with 
monotherapy compared to combination drug therapy in 
patients who survived the first 48 hours of infection of 
Pseudomonas bacteremia. In spite of the weaknesses of 
a retrospective analysis, no better data are available. 
Prospective, randomized controlled studies are needed 
to support this conclusion. 
It should also be stressed that effectiveness is not 
the only consideration dictating whether or not to use 
combination therapy, and preventing antibiotic resistance 
may be another important reason for choosing double 
therapy Thus, the choice of treatment should probably be 
tailored individually to each patient, according to various 
factors, such as the presence of neutropenia or septic 
shock, being hospitalized in the intensive care unit, length 
of hospitalization, previous antibiotic therapy, presence of 
renal failure, etc. It should be kept in mind, however, that 
certain antipseudomonal drugs are fully effective as 
monotherapy. 
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